ELMD vs. EMBC, CBLL, SMLR, KIDS, AXGN, AVNS, ZIMV, BVS, BFLY, and DCTH
Should you be buying Electromed stock or one of its competitors? The main competitors of Electromed include Embecta (EMBC), CeriBell (CBLL), Semler Scientific (SMLR), OrthoPediatrics (KIDS), AxoGen (AXGN), AVANOS MEDICAL (AVNS), ZimVie (ZIMV), Bioventus (BVS), Butterfly Network (BFLY), and Delcath Systems (DCTH). These companies are all part of the "medical equipment" industry.
Electromed vs. Its Competitors
Embecta (NASDAQ:EMBC) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.
Embecta has higher revenue and earnings than Electromed. Embecta is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.
Embecta has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Electromed has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.
Embecta currently has a consensus target price of $19.00, suggesting a potential upside of 61.98%. Electromed has a consensus target price of $33.50, suggesting a potential upside of 78.00%. Given Electromed's stronger consensus rating and higher possible upside, analysts plainly believe Electromed is more favorable than Embecta.
Electromed has a net margin of 11.34% compared to Embecta's net margin of 4.89%. Electromed's return on equity of 15.71% beat Embecta's return on equity.
In the previous week, Electromed had 4 more articles in the media than Embecta. MarketBeat recorded 8 mentions for Electromed and 4 mentions for Embecta. Electromed's average media sentiment score of 0.79 beat Embecta's score of 0.72 indicating that Electromed is being referred to more favorably in the news media.
93.8% of Embecta shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 0.4% of Embecta shares are held by company insiders. Comparatively, 14.0% of Electromed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Electromed beats Embecta on 11 of the 17 factors compared between the two stocks.
Get Electromed News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ELMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Electromed Competitors List
Related Companies and Tools
This page (NYSE:ELMD) was last updated on 7/25/2025 by MarketBeat.com Staff